News about Drug Discovery & Development

DFE Pharma expands its inhalation portfolio with the launch of Lactohale 400

Being a leader in Dry Powder Inhalation, DFE Pharma further expands its broad excipient portfolio of inhalation grade lactose
<br />

Drug Discovery & Development | 05/07/2022 | By Sudeep Soparkar |  897

Glenmark Pharma expand its OTC portfolio

Acquires approved ANDAs from Wockhardt

Drug Discovery & Development | 28/06/2022 | By Sudeep Soparkar |  662

Merck opens ?59 M CDMO facility to address critical cancer therapies

The 70,000 square foot facility, officially opened, brings 50 new jobs to the area

Drug Discovery & Development | 24/06/2022 | By Sudeep Soparkar |  650

Gericke ensures precise dosing operation with high-performance feeding unit

The right selection ensures recipe consistency and automated production to prevents product rejects

Drug Discovery & Development | 16/06/2022 | By Sudeep Soparkar |  361

I-Mab partners with MorphoSys

I-Mab partners with MorphoSys
Announces new license agreements for Felzartamab and TJ210

Drug Discovery & Development | 16/06/2022 | By Sudeep Soparkar |  795

Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML

Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death

Drug Discovery & Development | 13/06/2022 | By Sudeep Soparkar |  858

Autoimmune drug by Bristol Myers shows potential in lupus

Deucravacitinib is one of nine new drugs that Bristol Myers executives believe will help offset revenue losses

Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar |  804

PerkinElmer unveils ultrarapid whole-genome sequencing

The urWGS offering provides physicians with comprehensive, meaningful results in five days to help inform clinical management and improve outcomes

Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar |  541

BioNTech 2nd phase of Covid 19 trials completed

The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine

Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar |  694

US FDA approval for Incyte's Olumiant

Eli Lilly and Company and Incyte announced the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of Covid-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days.

Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar |  819